The FDA issued several updates this week regarding drugs that are currently in shortage. The updates below, which were released Thursday, are in addition to the shortages and discontinuations released Wednesday.
- Bumetanide Injection, USP (New – Currently in Shortage)
- Calcium Gluconate Injection (Updated – Currently in Shortage)
- Folic Acid Injection (Updated – Currently in Shortage)
- Imipenem and Cilastatin for Injection, USP (Updated – Currently in Shortage)
- Leucovorin Calcium Lyophilized Powder for Injection (Updated – Currently in Shortage)
- Lidocaine Hydrochloride (Xylocaine) Injection (Updated – Currently in Shortage)
- Memantine Hydrochloride (NAMENDA) Oral Solution (New – Discontinuation)
- Methylprednisolone Sodium Succinate for Injection, USP (Updated – Currently in Shortage)
- Morphine Sulfate Injection, USP (Updated – Currently in Shortage)
- Potassium Chloride Injection (Updated – Currently in Shortage)
- Potassium Phosphate Injection (Updated – Currently in Shortage)
- Rocuronium Bromide Injection (Updated – Currently in Shortage)
- Sodium Chloride 23.4% Injection (Updated – Currently in Shortage)
- Sodium Phosphate Injection (Updated – Currently in Shortage)
According to the FDA:
“A drug receives Resolved status when the Drug Shortages Staff (DSS) determines that the market is covered, based on information from all manufacturers. The market is considered covered when supply is available from at least one manufacturer to cover total market demand. However, some manufacturers may not have all presentations available. DSS monitors the supply of products with Resolved status. For the most current supply information, contact the manufacturers.”
(Source: U.S. Food & Drug Adminstration)
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!